http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2021393737-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_17db21f6c69dcc1028d6797c5b0d92fc http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b603ecd95b3b1497ae9f30752a676c0e |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-164 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-744 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-744 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 |
| filingDate | 2019-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_75d7c39cd0e0fc67e923011e5defc939 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_36ade61cd542b1bae2c5c08f966ce512 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c4dbeaa621defd5891d82871ec3041a9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c03e64861e1648f33c220eeeb2cda0e7 |
| publicationDate | 2021-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2021393737-A1 |
| titleOfInvention | Use of mam polypeptides for the treatment of obesity and obesity-related disorders |
| abstract | The development of obesity is still increasing worldwide. Likewise, metabolic syndrome, which is a collection of obesity-associated disorders, is associated with development of cardiovascular diseases, insulin resistance, hepatic steatosis, certain types of cancer and type 2 diabetes. Recently, seven peptides were isolated from F.prausnitzii and were shown as deriving from a single Microbial Anti-inflammatory Molecule (MAM). The inventors shows that L-MAM treatment prevented animals from development of High-Fat Diet-induced obesity. L-MAM treated mice significantly gained less weight throughout the gavage as compared to HFD-fed control experiment. The difference in body weight between L-MAM-treated animals on a HFD and the remaining animals is largely due to a significant reduction in the percentage of fat mass and a significant increase in the percentage of lean mass. Oral glucose tolerance testing (OGTT) revealed that chronic administration of L-MAM increased glucose tolerance. Finally, all adipose tissues weights were lower in L-MAM-treated mice. Accordingly, the present invention relates to the use of MAM polypeptides for the treatment of obesity and obesity-related disorders. |
| priorityDate | 2018-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 346.